Symbols

Symbols

Aime

Products

News

Markets

Watchlist

Brokers

News/

Stock/

PFSA

PFSA News

Newswire

08:31

Profusa shares surge 19.94% premarket as late-breaking clinical trial update accepted for Paris Vascular Insights 2025 presentation.

08:19

Profusa's Oxygen Tissue Monitoring Platform Evaluated in Peripheral Artery Disease Study

08:16

Profusa to Present Late-Breaking U.S.-Based Clinical Trial Update at Paris Vascular Insights 2025: Evaluating Lumee Oxygen Tissue Monitoring Platform in Peripheral Artery Disease Patients.

05:16

Profusa shares rise 10.24% premarket after recapitalization cuts debt to $14M and achieves key 2026 revenue milestones.

17:48

Profusa Achieves Key Milestones, Reduces Net Debt to $14 Million, and Sets Sights on $200-$250 Million in Revenue by 2030.

View More

About PFSA

Charts

--

Sector--

Established Date--

Listing Date--

Exchange--

Full-time Employees--

Fiscal Year Ends--

Website

Security Type--

Office address

Business

Introduction

View More